Sakai, Tetsuya
Udagawa, Hibiki http://orcid.org/0000-0001-8822-2684
Matsumoto, Shingo
Yoh, Kiyotaka
Nosaki, Kaname
Ikeda, Takaya
Zenke, Yoshitaka
Kirita, Keisuke
Niho, Seiji
Akimoto, Tetsuo
Goto, Koichi
Ishii, Genichiro
Article History
Received: 5 August 2020
Accepted: 24 September 2020
First Online: 30 September 2020
Compliance with ethical standards
:
: T. Sakai reports personal fees from AstraZeneca, outside the submitted work, H. Udagawa reports grants and personal fees from MSD, during the conduct of the study; grants and personal fees from Abbvie, grants and personal fees from Daiichisankyo; grants and personal fees from AMGEN, personal fees from Boehringer Ingelheim, grants and personal fees from AstraZeneca, personal fees from Chugai, personal fees from ONO, personal fees from Springer Japan, personal fees from Amco, personal fees from Taiho, outside the submitted work, K. Nosaki reports personal fees from MSD K.K., during the conduct of the study; personal fees from Nippon Kayaku Co., Ltd., personal fees from AstraZeneca K.K., personal fees from Bristol-Myers Squibb, personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Eli Lilly Japan K.K., personal fees from Pfizer Japan Inc., personal fees from Taiho Pharmaceutical Co., Ltd., outside the submitted work, Y. Zenke reports grants and personal fees from MSD, during the conduct of the study; grants from Merck, personal fees from Boheringer-Ingelhaeim, personal fees from Astrazeneca, personal fees from chugai, personal fees from Ono Pharmaceutical, personal fees from Bristol-Myers Squibb, personal fees from Lilly, personal fees from TAIHO Pharmacutical, outside the submitted work, K. Kirita reports grants and personal fees from MSD, during the conduct of the study; grants and personal fees from Pfizer, personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from Olympus, personal fees from Boston Scientific, personal fees from Amuco, personal fees from Kyowa Hakko Kirin, personal fees from Meiji Seika Kaisha, grants and personal fees from Chugai Pharma, outside the submitted work, S. Matsumoto reports grants from MSD, during the conduct of the study; grants from Novartis, grants from Chugai Pharma, grants from Merck, outside the submitted work, K. Yoh reports grants from MSD, during the conduct of the study; grants and personal fees from Chugai Pharma, grants and personal fees from AstraZeneca, grants and personal fees from Lilly, personal fees from Boehringer Ingelheim, grants and personal fees from Ono Pharmaceutical, grants and personal fees from Novartis, grants from Bayer, grants from Pfizer, grants and personal fees from MSD, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Taiho Pharmaceutical, personal fees from Kyowa Kirin, grants and personal fees from Daiichi Sankyo, grants from Takeda, outside the submitted work, S. Niho reports grants and personal fees from MSD, during the conduct of the study; grants and personal fees from AstraZeneca, grants and personal fees from Pfizer, grants and personal fees from Eli Lilly, grants and personal fees from Chugai, personal fees from Boehringer Ingelheim, personal fees from Taiho, personal fees from Bristol Myers Squibb, personal fees from Novartis, personal fees from Shionogi, personal fees from Ono, grants from Merck Biopharma, outside the submitted work, K. Goto reports grants and personal fees from MSD K.K., during the conduct of the study; grants and personal fees from AstraZeneca K.K, grants and personal fees from Pfizer Japan Inc., grants from Merck Biopharma Co., Ltd., grants and personal fees from Eli Lilly Japan K.K., grants from Xcoo, Inc., grants and personal fees from Thermo Fisher Scientific K.K., grants and personal fees from Ono Pharmaceutical Co., Ltd., grants and personal fees from Novartis Pharma K.K., grants and personal fees from TAIHO PHARMACEUTICAL CO., LTD., grants and personal fees from CHUGAI PHARMACEUTICAL CO., LTD., grants and personal fees from Nippon Boehringer lngelheim Co., Ltd., grants and personal fees from Takeda Pharmaceutical Company Limited, personal fees from Otsuka Pharmaceutical Co., Ltd., grants from Astellas Pharma Inc., grants from Guardant Health Inc., grants and personal fees from Janssen Pharmaceutical K.K., grants and personal fees from Kyowa Kirin Co., Ltd., grants and personal fees from DAIICHI SANKYO Co., Ltd., grants from Eisai Co., Ltd, grants from Sumitomo Dainippon Pharma Co., Ltd., grants from RIKEN GENESIS CO., LTD., grants from Ignyta,Inc., grants from Loxo Oncology, Inc., grants from Sysmex Corporation, grants from MEDICAL & BIOLOGICAL LABORATORIES CO., LTD., grants from Amgen Inc, outside the submitted work, G. Ishii reports grants from Miraca holdings, grants from Ono, grants from Daiichisankyo, outside the submitted work. The remaining authors declare no conflict of interest.
: This study was conducted with the approval of the Institutional Review Board of the National Cancer Center. The approval number for this study was 2019-098 and 2018-134. All the methods were performed in accordance with the approved guidelines.
: All the specimens and data were collected after obtaining written comprehensive informed consent from the patients.
: Consent was obtained.